Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Express Scripts
Johnson and Johnson
AstraZeneca
Dow

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for CC-122

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for CC-122?

CC-122 is an investigational drug.

There have been 13 clinical trials for CC-122. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2019.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Non-Hodgkin, and Lymphoma, Large B-Cell, Diffuse. The leading clinical trial sponsors are Celgene Corporation, Celgene, and H. Lee Moffitt Cancer Center and Research Institute.

There are thirty-six US patents protecting this investigational drug and four hundred and three international patents.

Recent Clinical Trials for CC-122
TitleSponsorPhase
Avadomide (CC-122) in Combination With Nivolumab in Advanced MelanomaBristol-Myers SquibbPhase 2
Avadomide (CC-122) in Combination With Nivolumab in Advanced MelanomaCelgene CorporationPhase 2
Avadomide (CC-122) in Combination With Nivolumab in Advanced MelanomaH. Lee Moffitt Cancer Center and Research InstitutePhase 2

See all CC-122 clinical trials

Clinical Trial Summary for CC-122

Top disease conditions for CC-122
Top clinical trial sponsors for CC-122

See all CC-122 clinical trials

US Patents for CC-122

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CC-122   Start Trial Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)   Start Trial
CC-122   Start Trial Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies Celgene Corporation (Summit, NJ)   Start Trial
CC-122   Start Trial Formulations of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione Celgene Corporation (Summit, NJ)   Start Trial
CC-122   Start Trial Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast Celgene Corporation (Summit, NJ)   Start Trial
CC-122   Start Trial Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases CELGENE CORPORATION (Summit, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CC-122

Drugname Country Document Number Estimated Expiration Related US Patent
CC-122 European Patent Office 3313818 2035-06-26   Start Trial
CC-122 Japan 2018527302 2035-06-26   Start Trial
CC-122 World Intellectual Property Organization (WIPO) 2016210262 2035-06-26   Start Trial
CC-122 Australia 2015305449 2034-08-22   Start Trial
CC-122 Brazil 112017003620 2034-08-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Medtronic
Harvard Business School
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.